Phase II Trial of Velcade (Bortezomib) in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-diagnosed Glioblastoma Multiforme
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2016
At a glance
- Drugs Bortezomib (Primary) ; Temozolomide
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 08 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2017.
- 07 Jan 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
- 07 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.